2. >>Business Strategy

SERB And BTG SP – A Simple Jigsaw

 
• By Ashley Yeo

The merging of the capabilities of Belgium’s SERB and the UK’s BTG Specialty Pharma could produce the world’s biggest antidotes manufacturer.

focal point - shutterstock

After a process lasting nearly a year and management presentations to multiple potential buyers, Boston Scientific CEO Mike Mahoney settled on SERB Specialty Pharmaceuticals, a Belgian company with a French culture and French CEO in Jeremie Urbain, as the company to buy out BTG plc’s Specialty Pharma business.

Despite its francophone roots, SERB insists on English as the day-to-day business language, which is an acknowledgement of its global...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By David Wild

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

More from In Vivo